Abstract
Food allergy affects an estimated 8% of children in the US, with increasing severity and global prevalence1. Oral immunotherapy (OIT) is a recently approved treatment with outcomes ranging from sustained tolerance to food allergen to no apparent benefit2,3. The immunological underpinnings that influence clinical outcomes of OIT still remain largely unresolved. Using single-cell RNA sequencing and paired TCRα/β sequencing, we assessed the transcriptomes of CD154+ and CD137+ peanut-reactive T helper cells from 12 peanut-allergic patients longitudinally throughout OIT. We observed expanded populations of cells expressing Th1, Th2, and Th17 signatures that further separated into six clonally distinct subsets, including a Tfh1-like, a Tfh2-like, a Th2A-like, and a Th2reg-like subset. Four of these subsets demonstrated convergence of TCR sequences, suggesting antigen-driven T cell fate. Although we observed suppression during OIT of Th2 and Th1 gene signatures within effector clonotypes, Tfh clonotypes were unaffected. We also did not observe significant clonal deletion or induction among the antigen-reactive T cells characterized. Positive outcomes were associated with larger decrease of Th2 signatures in Th2A-like cells, while treatment failure was associated with high baseline inflammatory gene signatures that were unmodulated by OIT. These signatures, including expression of OX40, OX40L, STAT1, and GPR15, were most clearly present in Th1 and Th17 clonotypes, but were also more broadly detected across the CD154+ CD4 population. These results demonstrate that differential clinical response is associated both with pre-existing trait characteristics of the CD4 immune compartment and with susceptibility to modulation by OIT.
Conflict of Interest Statement A.A.T., T.M.G., J.C.L., and the Massachusetts Institute of Technology have filed patents related to the single-cell sequencing methods used in this work. J.C.L. has interests in Sunflower Therapeutics PBC, Pfizer, Honeycomb Biotechnologies, OneCyte Biotechnologies, SQZ Biotechnologies, Alloy Therapeutics, QuantumCyte, Amgen, and Repligen. J.C.L.’s interests are reviewed and managed under Massachusetts Institute of Technology’s policies for potential conflicts of interest. J.C.L. receives sponsored research support at MIT from Amgen, the Bill & Melinda Gates Foundation, Biogen, Pfizer, Roche, Takeda, and Sanofi. The spouse of J.C.L. is an employee of Sunflower Therapeutics PBC. T.M.G. is currently an employee of Honeycomb Biotechnologies, Inc. A.A.T. is currently an employee of Immunitas Therapeutics, Inc. W.G.S. is a consultant of Aimmune Therapeutics.
Competing Interest Statement
A.A.T., T.M.G., J.C.L., and the Massachusetts Institute of Technology have filed patents related to the single-cell sequencing methods used in this work. J.C.L. has interests in Sunflower Therapeutics PBC, Pfizer, Honeycomb Biotechnologies, OneCyte Biotechnologies, SQZ Biotechnologies, Alloy Therapeutics, QuantumCyte, Amgen, and Repligen. The interests of J.C.L. are reviewed and managed under the Massachusetts Institute of Technology policies for potential conflicts of interest. J.C.L. receives sponsored research support at MIT from Amgen, the Bill & Melinda Gates Foundation, Biogen, Pfizer, Roche, Takeda, and Sanofi. The spouse of J.C.L. is an employee of Sunflower Therapeutics PBC. T.M.G. is currently an employee of Honeycomb Biotechnologies, Inc. A.A.T. is currently an employee of Immunitas Therapeutics, Inc. W.G.S. is a consultant of Aimmune Therapeutics.
Clinical Trial
NCT01750879
Funding Statement
The clinical work was performed in the Harvard Clinical and Translational Science Center supported by grants 1UL1TR001102 and 8UL1TR000170 from the National Center for Advancing Translational Sciences, and 1UL1RR025758 from the National Center for Research Resources. In addition, we thank our colleagues at the MGH Department of Pathology Flow and Image Cytometry Research Core for their help with cell sorting. The Flow Core obtained funding from the National Institutes of Health Shared Instrumentation program (1S10OD012027-01A1, 1S10OD016372-01, 1S10RR020936-01, and 1S10RR023440-01A1). This work was supported in part by the Koch Institute Support (core) NIH Grant P30-CA14051 from the National Cancer Institute, as well as the Koch Institute - Dana-Farber/Harvard Cancer Center Bridge Project. This work was also supported by the Food Allergy Science Initiative at the Broad Institute and the NIH (5P01AI039671, 5U19AI089992, U19AI095261).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Peanut-allergic individuals age 7 years and older were enrolled in a peanut OIT trial (NCT01750879) at the Food Allergy Center at Massachusetts General Hospital. All subjects were recruited with informed consent, and the study was approved by the Institutional Review Board of Partners Healthcare (protocol 2012P002153).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
FASTQ file format data related to human samples will be available through dbGaP under accession number phs001897.v1.p1. Processed gene expression and associated TCR clonotype data will be available through GEO under accession number GSE158667. Processed data files and associated meta data tables for Figures 1-4 will be made available on https://github.com/mitlovelab/, or upon request.